Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease
Identifieur interne : 003457 ( Main/Exploration ); précédent : 003456; suivant : 003458Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease
Auteurs : David Burn [Royaume-Uni] ; Murat Emre [Turquie] ; Ian Mckeith [Royaume-Uni] ; Peter Paul De Deyn [Belgique] ; Dag Aarsland [Norvège] ; Chuanchieh Hsu [États-Unis] ; Roger Lane [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Analysis of Variance, Cholinesterase, Cholinesterase Inhibitors (therapeutic use), Dementia, Dementia (complications), Dementia (drug therapy), Dementia (etiology), Double-Blind Method, Female, Follow-Up Studies, Hallucinations (drug therapy), Hallucinations (etiology), Human, Humans, Male, Nervous system diseases, Neuropsychological Tests (statistics & numerical data), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (etiology), Parkinson disease, Parkinson's disease, Phenylcarbamates (therapeutic use), Prospective Studies, Rivastigmine, Treatment Outcome, Visual hallucination, cholinesterase inhibitor, dementia, rivastigmine, visual hallucinations.
- MESH :
- chemical , therapeutic use : Cholinesterase Inhibitors, Phenylcarbamates.
- complications : Dementia, Parkinson Disease.
- drug therapy : Dementia, Hallucinations, Parkinson Disease.
- etiology : Dementia, Hallucinations, Parkinson Disease.
- statistics & numerical data : Neuropsychological Tests.
- Aged, Aged, 80 and over, Analysis of Variance, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Prospective Studies, Treatment Outcome.
Abstract
We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). This was a 24‐week double‐blind placebo‐controlled study. Primary efficacy measures were the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and Alzheimer's Disease Cooperative Study–Clinician's Global Impression of Change (ADCS‐CGIC). Secondary efficacy measures included activities of daily living, behavioral symptoms, and executive and attentional functions. Patients were stratified according to the presence of visual hallucinations at baseline. The study included 188 visual hallucinators (118 on rivastigmine, 70 on placebo) and 348 nonvisual hallucinators (239 on rivastigmine, 109 on placebo). Rivastigmine provided benefits in both visual hallucinators and nonvisual hallucinators. Absolute responses to rivastigmine on the ADAS‐cog were comparable over 6 months, although rivastigmine–placebo differences tended to be larger in visual hallucinators (4.27; P = 0.002) than in nonhallucinators (2.09; P = 0.015). On the ADCS‐CGIC, differences between rivastigmine and placebo were 0.5 in visual hallucinators (P = 0.030) and 0.3 in nonhallucinators (P = 0.111). Rivastigmine provided benefits on all secondary efficacy measures, and placebo declines and treatment differences were more marked in visual hallucinators. Adverse events were reported more frequently by rivastigmine‐treated patients, although this difference was less marked in visual hallucinators. Visual hallucinations appear to predict more rapid decline and possibly greater therapeutic benefit from rivastigmine treatment in PDD. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21077
Affiliations:
- Belgique, Norvège, Royaume-Uni, Turquie, États-Unis
- New Jersey, Province d'Anvers
- Anvers
- Université d'Anvers
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F69
- to stream Istex, to step Curation: 000F69
- to stream Istex, to step Checkpoint: 001F17
- to stream PubMed, to step Corpus: 002B07
- to stream PubMed, to step Curation: 002B07
- to stream PubMed, to step Checkpoint: 002D48
- to stream Ncbi, to step Merge: 001832
- to stream Ncbi, to step Curation: 001832
- to stream Ncbi, to step Checkpoint: 001832
- to stream Main, to step Merge: 004771
- to stream PascalFrancis, to step Corpus: 001915
- to stream PascalFrancis, to step Curation: 001406
- to stream PascalFrancis, to step Checkpoint: 001B18
- to stream Main, to step Merge: 004C13
- to stream Main, to step Curation: 003457
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease</title><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></author><author><name sortKey="Mckeith, Ian" sort="Mckeith, Ian" uniqKey="Mckeith I" first="Ian" last="Mckeith">Ian Mckeith</name></author><author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name></author><author><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name></author><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CA2855DAAB4079FC0C0635214C2D818C9F9F328C</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21077</idno><idno type="url">https://api.istex.fr/document/CA2855DAAB4079FC0C0635214C2D818C9F9F328C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F69</idno><idno type="wicri:Area/Istex/Curation">000F69</idno><idno type="wicri:Area/Istex/Checkpoint">001F17</idno><idno type="wicri:doubleKey">0885-3185:2006:Burn D:effects:of:rivastigmine</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16960863</idno><idno type="wicri:Area/PubMed/Corpus">002B07</idno><idno type="wicri:Area/PubMed/Curation">002B07</idno><idno type="wicri:Area/PubMed/Checkpoint">002D48</idno><idno type="wicri:Area/Ncbi/Merge">001832</idno><idno type="wicri:Area/Ncbi/Curation">001832</idno><idno type="wicri:Area/Ncbi/Checkpoint">001832</idno><idno type="wicri:doubleKey">0885-3185:2006:Burn D:effects:of:rivastigmine</idno><idno type="wicri:Area/Main/Merge">004771</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0021716</idno><idno type="wicri:Area/PascalFrancis/Corpus">001915</idno><idno type="wicri:Area/PascalFrancis/Curation">001406</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B18</idno><idno type="wicri:doubleKey">0885-3185:2006:Burn D:effects:of:rivastigmine</idno><idno type="wicri:Area/Main/Merge">004C13</idno><idno type="wicri:Area/Main/Curation">003457</idno><idno type="wicri:Area/Main/Exploration">003457</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease</title><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Regional Neuroscience Center, Newcastle General Hospital, Newcastle‐upon‐Tyne</wicri:regionArea><wicri:noRegion>Newcastle‐upon‐Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul Faculty of Medicine, Istanbul University, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Mckeith, Ian" sort="Mckeith, Ian" uniqKey="Mckeith I" first="Ian" last="Mckeith">Ian Mckeith</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Regional Neuroscience Center, Newcastle General Hospital, Newcastle‐upon‐Tyne</wicri:regionArea><wicri:noRegion>Newcastle‐upon‐Tyne</wicri:noRegion></affiliation></author><author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name><affiliation wicri:level="4"><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Neurology, University of Antwerp, Wilrijk‐Antwerp</wicri:regionArea><orgName type="university">Université d'Anvers</orgName><placeName><settlement type="city">Anvers</settlement><region type="district" nuts="2">Province d'Anvers</region></placeName></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Research Center for Neuropsychiatry and Geriatric Psychiatry, Stavanger University Hospital, Stavanger</wicri:regionArea><wicri:noRegion>Stavanger</wicri:noRegion></affiliation></author><author><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Nervous System Clinical Research, Novartis Pharmaceutical, East Hanover, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Nervous System Clinical Research, Novartis Pharmaceutical, East Hanover, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-11">2006-11</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1899">1899</biblScope><biblScope unit="page" to="1907">1907</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CA2855DAAB4079FC0C0635214C2D818C9F9F328C</idno><idno type="DOI">10.1002/mds.21077</idno><idno type="ArticleID">MDS21077</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Cholinesterase</term><term>Cholinesterase Inhibitors (therapeutic use)</term><term>Dementia</term><term>Dementia (complications)</term><term>Dementia (drug therapy)</term><term>Dementia (etiology)</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Hallucinations (drug therapy)</term><term>Hallucinations (etiology)</term><term>Human</term><term>Humans</term><term>Male</term><term>Nervous system diseases</term><term>Neuropsychological Tests (statistics & numerical data)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (etiology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Phenylcarbamates (therapeutic use)</term><term>Prospective Studies</term><term>Rivastigmine</term><term>Treatment Outcome</term><term>Visual hallucination</term><term>cholinesterase inhibitor</term><term>dementia</term><term>rivastigmine</term><term>visual hallucinations</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cholinesterase Inhibitors</term><term>Phenylcarbamates</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term><term>Hallucinations</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dementia</term><term>Hallucinations</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Neuropsychological Tests</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Prospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cholinesterase</term><term>Démence</term><term>Hallucination visuelle</term><term>Homme</term><term>Parkinson maladie</term><term>Rivastigmine</term><term>Système nerveux pathologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). This was a 24‐week double‐blind placebo‐controlled study. Primary efficacy measures were the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and Alzheimer's Disease Cooperative Study–Clinician's Global Impression of Change (ADCS‐CGIC). Secondary efficacy measures included activities of daily living, behavioral symptoms, and executive and attentional functions. Patients were stratified according to the presence of visual hallucinations at baseline. The study included 188 visual hallucinators (118 on rivastigmine, 70 on placebo) and 348 nonvisual hallucinators (239 on rivastigmine, 109 on placebo). Rivastigmine provided benefits in both visual hallucinators and nonvisual hallucinators. Absolute responses to rivastigmine on the ADAS‐cog were comparable over 6 months, although rivastigmine–placebo differences tended to be larger in visual hallucinators (4.27; P = 0.002) than in nonhallucinators (2.09; P = 0.015). On the ADCS‐CGIC, differences between rivastigmine and placebo were 0.5 in visual hallucinators (P = 0.030) and 0.3 in nonhallucinators (P = 0.111). Rivastigmine provided benefits on all secondary efficacy measures, and placebo declines and treatment differences were more marked in visual hallucinators. Adverse events were reported more frequently by rivastigmine‐treated patients, although this difference was less marked in visual hallucinators. Visual hallucinations appear to predict more rapid decline and possibly greater therapeutic benefit from rivastigmine treatment in PDD. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Belgique</li><li>Norvège</li><li>Royaume-Uni</li><li>Turquie</li><li>États-Unis</li></country><region><li>New Jersey</li><li>Province d'Anvers</li></region><settlement><li>Anvers</li></settlement><orgName><li>Université d'Anvers</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name></noRegion><name sortKey="Mckeith, Ian" sort="Mckeith, Ian" uniqKey="Mckeith I" first="Ian" last="Mckeith">Ian Mckeith</name></country><country name="Turquie"><noRegion><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></noRegion></country><country name="Belgique"><region name="Province d'Anvers"><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name></region></country><country name="Norvège"><noRegion><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name></noRegion></country><country name="États-Unis"><region name="New Jersey"><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name></region><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003457 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003457 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CA2855DAAB4079FC0C0635214C2D818C9F9F328C
|texte= Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |